Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and PK Study of Eliapixant in Healthy Volunteers
NCT03773068Phase 1Completed
- Sponsor
- Bayer
- Start
- Dec 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eliapixant in refractory chronic cough (RCC) (3 arms), sponsored by Bayer. Primary endpoints: Absolute oral bioavailability of BAY1817080 up to 10 days and Relative bioavailability of Formulation A versus Formulation B up to 10 days. Started Dec 2018; status: completed.
02
Drugs
eliapixant
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on NCT03773068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03773068.